June 9, 2021

FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?

Thumbnail

FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?

About This Episode

The Food and Drug Administration (FDA) has approved aducanumab as a new treatment for early-stage Alzheimer’s disease, and this AlzTalks explores what this means for the Alzheimer’s community.

Host Meryl Comer talked about the drug treatment with Biogen’s Samantha Budd Haeberlein, PhD, SVP, Head of Neurodegeneration Development and Karin Hellsvik, Head, External Communications and Patient Advocacy, and had a conversation about the decision with George Vradenburg, chairman and co-founder of UsAgainstAlzheimer’s; Russ Paulsen, UsA’s chief operating officer; and Jason Resendez, executive director of the UsAgainstAlzheimer’s Center for Brain Health Equity. 

Meryl Comer also spoke about this new drug with advocates Jim and Geri Taylor. Geri, who lives with Alzheimer’s disease, participated in the clinical trial for this therapy.

Press the 'Play' button under the image at left to hear a podcast of the conversation, or watch the full session HERE.

BrainStorm Feed

120

The Financial Toll of Caregiving with Ken and Maddy Dychtwald

It is time to treat caregiving as a societal issue rather than a private family matter. More than 32 million Americans are financial caregivers for

LISTEN NOW
119

The Fine Print on Your Prescriptions: What Families Need to Know About Medicare Part D

You picked a Medicare drug plan in December. Then in January, the pharmacist tells you your medication isn’t covered, or that it needs approval first

LISTEN NOW
118

Risky Business: The Costliest Assumptions for Medicare Families

In part one of BrainStorm’s look at Medicare open enrollment, host Meryl Comer talks with Alison Schneider, Director of Market Access Policy and Strategy at

LISTEN NOW